206559-39-9

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMO-2-CHLOROBENZHYDRAZIDE is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 4-BROMO-2-CHLOROBENZHYDRAZIDE is employed as a precursor in the production of agrochemicals, aiding in the creation of compounds that can protect crops from pests and diseases.
Used as a Reagent in Organic Synthesis:
4-BROMO-2-CHLOROBENZHYDRAZIDE is used as a reagent in the preparation of benzhydrazone derivatives and other organic compounds, facilitating the synthesis of complex organic molecules for various applications.

InChI:InChI=1/C7H6BrClN2O/c8-4-1-2-5(6(9)3-4)7(12)11-10/h1-3H,10H2,(H,11,12)

Upstream product

• 59748-90-2 4-Bromo-2-chloro-benzoic Acid 
• 185312-82-7 4-bromo-2-chlorobenzoic acid methyl ester 

Relevant academic research and scientific papers

5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma

Through a phenotypic high-throughput screen using a serum response element luciferase promoter, we identified a novel 5-aryl-1,3,4-oxadiazol-2-ylthiopropionic acid lead inhibitor of Rho/myocardin-related transcription factor (MRTF)/serum response factor (SRF)-mediated gene transcription with good potency (IC50 = 180 nM). We were able to rapidly improve the cellular potency by 5 orders of magnitude guided by sharply defined and synergistic SAR. The remarkable potency and depth of the SAR, as well as the relatively low molecular weight of the series, suggests, but does not prove, that binding to the unknown molecular target may be occurring through a covalent mechanism. The series nevertheless has no observable cytotoxicity up to 100 μM. Ensuing pharmacokinetic optimization resulted in the development of two potent and orally bioavailable anti-fibrotic agents that were capable of dose-dependently reducing connective tissue growth factor gene expression in vitro as well as significantly reducing the development of bleomycin-induced dermal fibrosis in mice in vivo.